Analyst Price Target is $55.75
▲ +47.33% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is $55.75, with a high forecast of $86.00 and a low forecast of $14.00. The average price target represents a 47.33% upside from the last price of $37.84.
Current Consensus is
The current consensus among 16 investment analysts is to hold stock in Editas Medicine. This rating has held steady since February 2020, when it changed from a Buy consensus rating.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.